The involvement of the MET oncogene in de novo and acquired resistance of non-small cell lung cancers (NSCLCs) to tyrosine kinase inhibitors (TKIs) has previously been reported, but the precise mechanism by which MET overexpression contributes to TKI-resistant NSCLC remains unclear. MicroRNAs (miRNAs) negatively regulate gene expression, and their dysregulation has been implicated in tumorigenesis. To understand their role in TKI-resistant NSCLCs, we examined changes in miRNA that are mediated by tyrosine kinase receptors. Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C « (PKC-«) and sarcoma viral oncogene homolog (SRC). These findings suggest that modulation of specific miRNAs may provide a therapeutic approach for the treatment of NSCLCs. npg
a r t i c l e s MiRNAs repress gene expression by inhibiting mRNA translation or by promoting mRNA degradation and are considered to be master regulators of various processes, ranging from proliferation 1 to apoptosis 2 . Both loss and gain of miRNA function contribute to cancer development through the upregulation and silencing, respectively, of different target genes. Altered miRNA expression in various human tumor types has been observed, and key roles for miRNAs in cancer pathogenesis and the response to therapy have been shown 3, 4 . NSCLCs account for approximately 85% of all cases of lung cancer 5 . Although NSCLC is a remarkably heterogeneous disease that includes distinct morphological and molecular subtypes, activation of epidermal growth factor receptor (EGFR) and MET (the receptor tyrosine kinase (RTK) for hepatocyte growth factors) is common and is associated with stimulation of the rat sarcoma (RAS)-mitogen-activated protein kinase 1 (ERK) and the phosphoinositide-3-kinase (PI3K)-v-akt murine thymoma viral oncogene homolog 1 (AKT) axes, which leads to NSCLC cell proliferation, survival and invasion 6 . The TKIs gefitinib and erlotinib effectively target EGFR in individuals with NSCLC, but these therapeutic agents are ultimately limited by the emergence of mutations and other molecular mechanisms conferring drug resistance 7 .
MET protein expression and phosphorylation have been associated with both primary and acquired resistance to EGFR TKI therapy in NSCLC patients 8, 9 , strongly implicating MET as an effective therapeutic target to overcome resistance to this important class of drugs in lung cancer 10 . Here we show that EGF and MET receptors, by modulating specific miRNAs, control gefitinib-induced apoptosis and NSCLC tumorigenesis. Our results are, to our knowledge, the first to identify EGF-and MET-receptor-regulated miRNAs representing oncogenic signaling networks in NSCLCs.
RESULTS

MiRNAs modulated by both EGFR and MET
To identify EGFR-and MET-regulated miRNAs, we stably silenced EGFR and MET in Calu-1 cells from the American Type Culture Collection (ATCC) using shRNA lentiviral particles ( Fig. 1a) and examined the global miRNA expression profiles. In EGFR-and METknockdown (EGFR-KD and MET-KD) Calu-1 cells, we identified 35 and 44 significantly (P < 0.05) dysregulated miRNAs, respectively ( Fig. 1b and Supplementary Fig. 1a ). MiRNAs with a greater than 1.5-fold (for EGFR) or a greater than 1.7-fold (for MET) change are shown. After comparing these two lists of miRNAs, we found only eight that were regulated by both EGFR and MET ( Fig. 1c) : miR-21, miR-221 and miR-222, miR-30b and miR-30c, miR-29a and miR-29c and miR-100. We initially focused on miR-30b, miR-30c, miR-221 and miR-222, which were downregulated after both MET and EGFR silencing and which showed the highest fold changes in expression. We also investigated the two miRNAs that were most differentially induced after MET silencing, miR-103 and miR-203, based on recent evidence indicating MET overexpression in de novo and acquired resistance to TKIs 8, 9 . We validated the expression of these six miRNAs in EGFR-KD and MET-KD Calu-1 cells using quantitative RT-PCR (qRT-PCR) (Supplementary Fig. 1b ) and northern blot ( Fig. 1d) analyses.
Tyrosine-kinase-modulated miRNA targets As MET and EGFR RTKs have a key role in lung cancer tumorigenesis and progression 11 , we hypothesized that miR-103 and miR-203 (which are increased after MET knockdown) are tumor suppressors and that miR-221, miR-222, miR-30b and miR-30c (which are decreased after MET and EGFR silencing) are oncogenic. Our search for A n t i-S c r A n t i-2 2 1 A n t i-2 2 2
A n t i-S c r A n t i-3 0 b A n t i-3 0 c npg a r t i c l e s mRNA targets using the TargetScan and PicTar computational tools revealed that the 3′ untranslated regions (3′ UTRs) of human APAF1, BCL2L11 (also known as BIM), PRKCE (also known as PKC-ε) and SRC contain evolutionarily conserved binding sites specific for miR-221 and miR-222, miR-30b and miR-30c, miR-103 and miR-203, respectively ( Supplementary Fig. 2a ). We focused on these genes based on their role in TKI sensitivity (BCL2L11 (BIM) and APAF1) 12, 13 or TKI resistance (SRC) 14 or in the negative allosteric modulation of EGFR signaling (PRKCE (PKC-ε)) 15 . To investigate whether the miRNAs directly interact with these four putative target genes, we cotransfected pGL3 3′ UTR luciferase reporter vectors with synthetic miR-103, miR-203, miR-221, miR-222, miR-30b and miR-30c. A decrease in luciferase activity indicated direct interactions between the miRNAs and the PRKCE (PKC-ε), SRC, APAF1 and BCL2L11 (BIM) 3′ UTRs (Fig. 1e) , and target gene repression was rescued by mutations or deletions in the complementary seed sites ( Fig. 1e and Supplementary Fig. 2a ). A western blot analysis showed an inverse correlation (P < 0.05) between miR-221, miR-222, miR-103, miR-203, miR-30b and miR-30c expression and the amount of target protein in an NSCLC cell panel ( Supplementary Fig. 2b,c) , which was confirmed by determining the Pearson correlation coefficients ( Fig. 1f and Supplementary Fig. 2d) . Results from the immunoblot analysis fully agreed with data obtained using reporter gene assays. Ectopic expression of miR-221, miR-222, miR-30b and miR-30c in H460 cells markedly decreased BIM and APAF-1 expression, and enforced expression of miR-103 and miR-203 clearly reduced the concentrations of PKC-ε and SRC protein ( Fig. 1g,h) . Conversely, knockdown of miR-221, miR-222, miR-30b and miR-30c increased the concentrations of APAF-1 and BIM protein ( Fig. 1i) . As MET knockdown Calu-1 cells showed an increase of APAF-1 and BIM concentrations and a decrease of PKC-ε and SRC concentrations ( Fig. 1j) , enforced expression of miR-221,miR-222, miR-30b and miR-30c in MET knockdown Calu-1 cells strongly reduced APAF-1 and BIM expression ( Supplementary Fig. 3a) , whereas miR-103 and miR-203 knockdown increased SRC and PKC-ε expression ( Supplementary Fig. 3b ). Collectively, these data indicate a direct correlation between change in expression of PKC-ε, SRC, APAF-1 and BIM proteins and these specific miRNAs after MET silencing in NSCLC cells ( Fig. 1g-j and Supplementary  Fig. 3a,b) . Detection of PKC-ε, SRC, APAF-1 and BIM proteins in vivo in 110 lung cancer specimens ( Supplementary Table 1 ) using miRNA in situ hybridization (ISH) followed by immunohistochemistry (IHC) showed a more significant negative correlation between these proteins and miR-103, miR-203, miR-221, miR-222, miR-30b and miR-30c in human tumors ( Supplementary Fig. 4b ). We observed an inverse correlation between miR-203 and SRC expression, miR-30c and BIM expression, miR-103 and PKC-ε expression and miR-222 and APAF-1 expression in the majority of the lung cancer tissues ( Supplementary Fig. 4a,b ). In addition, we saw MET overexpression in 52% (57/110) of the same 110 lung tumor samples (shown using miRNA ISH and MET IHC; Supplementary Fig. 5a ), and we saw low miR-103 and miR-203 expression and high miR-222 and miR-30c expression in tumors overexpressing MET ( Fig. 2a and Supplementary Fig. 5a) ; conversely, we observed high miR-103 and miR-203 and low miR-222 and miR-30c expression in tumors without MET expression. Notably, the majority of tumors overexpressing MET had accompanying metastases ( Supplementary  Fig. 5b) , indicating that MET-regulated miRNAs have a role in the metastatic spread of lung cancer cells. We extended our analysis to 40 independent lung tumors with an annotated clinical history ( Supplementary Table 2 ), which we divided into two groups of 'low' and 'high' MET and EGFR expression based on qRT-PCR analyses ( Fig. 2 and Supplementary  Fig. 5c ). An analysis of variance confirmed that the miRNAs (miR-30b and miR-30c and miR-221 and miR-222) were differentially expressed between the low and high groups, whereas using a Pearson coefficient, we identified an inverse correlation between MET and miR-103 and MET and miR-203 ( Fig. 2b,c) . We confirmed the qRT-PCR results using an IHC analysis for MET and EGFR (Supplementary Fig. 5d ). In addition, we observed MET overexpression in tumors that had distant metastases compared to nonmetastatic tumors, but there was no correlation between metastases and EGFR expression in these 40 lung cancers ( Fig. 2d and Supplementary Fig. 5e ).
Tyrosine-kinase-regulated miRNAs control gefitinib sensitivity
Having shown that EGFR regulates miR-221, miR-222, miR-30b and miR-30c, we investigated a role for these miRNAs in gefitinibinduced apoptosis in NSCLCs with wild-type EGFR (Calu-1 and A549 cells) compared to those with EGFR that has exon 19 deletions (PC9 and HCC827 cells). Calu-1 and A549 cells were completely resistant to all concentrations of gefitinib tested (up to 20 µM); in contrast, the growth of PC9 and HCC827 EGFR mutant cells was significantly inhibited, even at low doses (0.1 µM) of gefitinib ( Fig. 3a) , which is in agreement with results from a previous study 16 . Notably, after gefitinib treatment, we observed marked miR-30b, miR-30c, miR-221 and miR-222 downregulation and increased amounts of BIM and APAF-1 protein, only in PC9 and HCC827 gefitinib-sensitive cells (Fig. 3b,c) . In addition, as previously shown 16 , the concentration of phosphorylated ERKs was markedly lower in HCC827 and PC9 cells, but not in Calu-1 cells, compared to untreated cells (Fig. 3c) .
To directly assess the relevance of miR-30b, miR-30c, miR-221 and miR-222 in gefitinib-induced apoptosis, we analyzed the expression of these miRNAs in NSCLC cells with acquired gefitinib resistance, obtained after long-term exposure to increasing drug concentrations 8, 17 : PC9 gefitinib-resistant (PC9 GR) cells with an EGFR Thr790 that miR-221, miR-222, miR-30b and miR-30c expression did not decrease in HCC827 GR and PC9 GR cells (cells with acquired gefitinib resistance) exposed to 10 µM gefitinib for 24 h. All quantitative data were generated from a minimum of three replicates. Error bars, ± s.d. A two tailed Student's t test was used to determine the P values. *P < 0.001, **P < 0.05. npg a r t i c l e s alteration and HCC827 gefitinib-resistant (HCC827 GR) cells with MET amplification. In contrast to the gefitinib-responsive parental cells, we did not observe lower expression of miR-30b, miR-30c, miR-221 and miR-222 or modulation of their relative targets after treatment with gefitinib ( Fig. 3d and Supplementary Fig. 6a ). Of note, miR-30c, miR-221 and miR-222 overexpression in gefitinibsensitive HCC827 and PC9 cells rendered these cells less responsive to treatment with gefitinib compared to parental PC9 and HCC827 cells ( Fig. 4a and Supplementary Fig. 7a) , and knockdown of miR-30b, miR-30c, miR-221 and miR-222 led to increased gefitinib sensitivity in Calu-1, HCC827 GR and PC9 GR cells ( Fig. 4a  and Supplementary Fig. 7b) , indicating that these miRNAs are key modulators of TKI resistance.
To investigate the contribution of APAF-1 and BIM downregulation mediated by miR-30b, miR-30c, miR-221 and miR-222 to the cellular TKI response, we overexpressed APAF-1 and BIM in A549 gefitinib-resistant cells. We observed gefitinib-induced poly-(ADPribose) polymerase (PARP) cleavage in cells overexpressing BIM and APAF-1 but not in cells transfected with an empty vector plasmid (Fig. 4b) . Conversely, the response to gefitinib was reduced by BIM and APAF-1 silencing in gefitinib-sensitive HCC827 and PC9 cells (Fig. 4c) . We cloned wild-type and mutated 3′ UTRs of BIM and APAF-1 (which we used for luciferase assays; Fig. 1e ) downstream of BIM and APAF-1 coding sequences and performed caspase-3/7 and viability assays. We observed no increase in cell death after treatment with gefitinib of A549 cells cotransfected with wild-type 3′ UTRs for BIM and APAF-1 and with miR-30b, miR-30c, miR-221 and miR-222; conversely, miRNA binding-site mutations or deletions restored the apoptotic response to gefitinib, suggesting that the effects of both APAF-1 and BIM on gefitinib sensitivity were directly related to knockdown of these proteins mediated by miR-30b, miR-30c, miR-221 and miR-222 ( Fig. 4d and Supplementary Fig. 7c ).
Because MET overexpression is associated with gefitinib resistance and because miR-30b, miR-30c, miR-221 and miR-222 are also regulated by MET, we hypothesized that MET could mediate resistance to gefitinib treatment through the regulation of these miRNAs. Thus, we speculated that the simultaneous inhibition of MET and EGFR could overcome gefitinib resistance in NSCLCs. In support of this hypothesis, we observed downregulation of miR-30b, miR-30c, miR-221 and miR-222 in Calu-1 and A549 cells overexpressing MET (data not shown) after MET knockdown or treatment with the MET inhibitor SU11274 (Supplementary Fig. 8a,b ). In addition, we observed increased caspase-3/7 activity and decreased cell viability in SU11274treated Calu-1 and MET-KD Calu-1 cells that we exposed to different concentrations of gefitinib ( Supplementary Fig. 8c,d) . Taken together, these results suggest that MET overexpression induces resistance to gefitinib treatment in TKI-resistant Calu-1 cells through the upregulation of miR-30b, miR-30c, miR-221 and miR-222 and that inhibition of both EGFR and MET is needed to shut down these miRNAs and their survival effects.
Other miRNAs commonly deregulated by EGFR and MET, including miR-21, miR-29a, miR-29c and miR-100 ( Fig. 1c) , were downregulated in HCC827 and PC9 cells treated with gefitinib ( Supplementary Fig. 9a ). Of note, we did not observe downregulation of miR-21, miR-29a, miR-29c and miR-100 in HCC827 GR and PC9 GR cells after gefitinib treatment (Supplementary Fig. 9b) ; however, enforced expression of miR-21, miR-29a, miR-29c and miR-100 increased gefitinib resistance in HCC827 and PC9 cells (Supplementary Fig. 10a) . We therefore concluded that EGFR and MET control oncogenic signaling networks through common miRNAs. Recently, researchers from another study reported that miR-21 is downregulated after gefitinib treatment of NSCLC cells with EGFR activating mutations 18 . For this reason, we further investigated whether miR-21 knockdown by oligonucleotide inhibitors of miRNAs could restore gefitinib sensitivity in NSCLC cells with de novo or acquired resistance. MiR-21 knockdown increased sensitivity to gefitinib-induced apoptosis in A549, HCC827GR and PC9GR cells, suggesting that this miRNA has a major role in the EGFR-MET signaling pathway (Supplementary Fig. 11a,b) .
Next, we focused on miR-103 and miR-203, which are strongly downregulated in MET-expressing Calu-1 cells (Fig. 1d) . As expected, treatment of Calu-1 cells with SU11274 increased (P < 0.05) the expression of miR-103 and miR-203 ( Supplementary Fig. 12a ). Their targets, SRC and PKC-ε, exert pro-survival effects and contribute to gefitinib resistance by activating the AKT and ERK signaling pathways 14, 15 . Accordingly, overexpression of miR-103 and miR-203 in A549 cells was associated with reduced phosphorylation of AKT and its substrate glycogen synthase kinase 3 β (GSK3β) and reduced phosphorylation of the ERKs (Supplementary Fig. 13a) . Researchers previously reported that MET induces gefitinib resistance through persistent PI3K-AKT and ERK signaling activation 8 , and our results indicate that MET overexpression controls gefitinib resistance through activation of the AKT-ERK pathways and is mediated, at least in part, by miR-103 and miR-203. In agreement with the results from the previous study 8 , enforced expression of miR-103 or miR-203 or silencing of PKC-ε and SRC increased the sensitivity of Calu-1 cells to gefitinib (as assessed by caspase-3/7 and viability assays; Supplementary Fig. 13b,c) . Notably, we found that miR-103 and miR-203 expression decreased and SRC and PKC-ε expression consequently increased in HCC827 gefitinib-resistant cells with acquired MET amplification and gefitinib resistance 8 compared to the HCC827 parental cells, corroborating our hypothesis that MET controls the response to TKIs, at least in part through miR-103, miR-203 and their respective targets (Supplementary Fig. 13d,e ). Finally, to analyze sensitivity to gefitinib in vivo, we stably transfected A549 cells with GFP lentivirus constructs containing either full-length miR-103 or miR-203, or anti-miR-221 and anti-miR-30c. The magnification is the same for all the panels *P < 0.00001, **P < 0.001 relative to miRNA scrambled transfected cells. (c) Flow cytometric distributions of Calu-1 and A549 cells transfected with control miRNAs, miR-103 (103), miR-203 (203), control siRNA (Scr siRNA) and siRNAs of PKC-ε (siPKC-ε) and SRC (siSRC). The effect of miR-203 on the cell cycle is slightly stronger than that of miR-103, as assessed by the ratio between the G0-G1 and S phases. All quantitative values show mean ± s.d. n = 5. A two-tailed Student's t test was used to determine the P values for the G0-G1:S ratios. *P < 0.00001, **P < 0.005 compared to scrambled miRNA. Scr miR, scrambled miR; siScr, siRNA scrambled. Overexpression of miR-103 and miR-203 or knockdown of miR-221 and miR-30c resulted in marked inhibition of tumor growth and increased sensitivity to gefitinib-induced apoptosis in nude mice after 2 weeks of treatment (Fig. 4e,f and Supplementary Fig. 14a) . We confirmed the downregulation of miR-221 and miR-222 and the upregulation of miR-103 and miR-203 in the xenograft tumors by qRT-PCR (Supplementary Fig. 14b ).
MiR-103 and miR-203 reduce NSCLC cell migration
The anti-proliferative activity of miR-103 and miR-203 in various cancers has been previously reported [19] [20] [21] . To further investigate the functional role of miR-103 and miR-203 in NSCLC tumorigenesis, we assessed the effects of miR-103 and miR-203 gain of function and the loss of PKC-ε and SRC on cell migration and cell cycle kinetics. Migration was reduced by about 60% compared to controls in cells with increased miR-103 and miR-203 expression or decreased PRKCE (PKC-ε) and SRC expression ( Fig. 5a) . We further confirmed these results using a wound-healing assay (Fig. 5b) . In addition, A549 and Calu-1 cells transfected with miR-103, miR-203 or PRKCE (PKC-ε), and SRC siRNAs showed an increased G1 cell fraction and a corresponding decreased number of cells in the S and G2-M phases, with miR-203 and SRC siRNA having a slightly stronger effect as compared to miR-103 and PRKCE (PKC-ε) siRNA (Fig. 5c) .
MiR-103 and miR-203 promote the mesenchymal-to-epithelial An association between the epithelial-mesenchymal transition (EMT) and the development of chemoresistance, including resistance to EGFR-targeted therapy, that leads to recurrence of disease and metastasis has recently been reported 22 . Although identifying the molecular events underlying EMT is an area under intense investigation, what triggers the onset of the EMT in tumor cells is unknown. We observed a change in cellular shape of Calu-1 cells from a fibroblastoid morphology to an epithelial polarized phenotype after knockout of MET (Fig. 6a) , prompting us to further investigate whether this morphological change could be a result of a mesenchymal-toepithelial transition. We assessed the expression of key EMT-associated markers and observed, in Calu-1 MET knockdown cells compared to Calu-1 Sh controls (which encode a scrambled shRNA sequence that does not lead to the specific degradation of any known cellular mRNA), decreased expression of mesenchymal markers and increased E-cadherin expression ( Fig. 6b-d) , strongly indicating reversion of Calu-1 cells back to an epithelial phenotype after MET knockdown. Notably, in MET-KD cells, Snail protein expression was lower than in cells without MET knockdown, was localized to the cytoplasm (Fig. 6b ) and the protein itself was presumably nonfunctional 23 . It is notable that we did not observe a morphological change in EGFR-KD Calu-1 cells, in which miR-200c (refs. 24,25) , miR-103 and miR-203 were not upregulated, as was the case in MET knockdown cells ( Supplementary Fig. 1a) . To test whether miR-103 and miR-203 were involved in the mesenchymal-epithelial transition, we overexpressed these miRNAs in Calu-1 cells and observed downregulation of several mesenchymal markers and increased E-cadherin expression, indicating a role for these miRNAs in the mesenchymal-epithelial transition (Fig. 6e-g and Supplementary Fig. 15a,b) . In addition, silencing of PRKCE (PKC-ε) and SRC in Calu-1 cells increased the amount of E-cadherin and decreased the levels of SNAIL, ZEB1 (encoding zinc finger E-box binding 1), ZEB2 (encoding zinc finger E-box binding 2), vimentin and fibronectin mRNA compared to cells transfected with a siRNA control (Supplementary Fig. 15c ). Because it was recently reported that miR-103 targets Dicer 26 , we investigated the effects of Dicer knockdown on tumorigenesis and on gefitinib-induced apoptosis of NSCLCs. Notably, near complete Dicer knockdown reduced not only gefitinib resistance but also the migration and expression of the mesenchymal markers of NSCLC cells, suggesting that miR-103 could also be involved in the mesenchymal-epithelial transition process through Dicer downregulation (Supplementary Results and  Supplementary Fig. 16 ). In conclusion, by regulating the expression of specific miRNAs, MET orchestrates the convergence of several EMT-associated pathways, including the Dicer, SRC, PKC-ε and AKT pathways, supporting the possibility that MET targeting could be a strategy to control EMT and NSCLC progression.
DISCUSSION
A strong correlation between activating mutations in the EGFR tyrosine kinase domain and the response to erlotinib and gefitinib has been reported in several trials 27 . Different mechanisms of resistance to EGFR TKIs have also been described. The EGFR T790M mutation 17 , which reduces the affinity of the EGFR to gefitinib and erlotinib, and MET gene amplification produce acquired resistance to anti-EGFR agents 8 . The results of this study provide evidence that EGFR and MET receptor tyrosine kinases, through regulation of expression of specific miRNAs, control the metastatic behavior and gefitinib resistance of NSCLCs.
In a previous study, we identified MET as a regulator of miR-221 and miR-222 expression 3 . To better understand the pathway(s) involved in NSCLC tumorigenesis and drug resistance, we investigated miRNAs modulated by EGFR and MET tyrosine kinases. We focused on miR-30b, miR-30c, miR-221 and miR-222, which are regulated by both EGFR and MET, and miR-103 and miR-203, which are regulated by MET only. We show that gefitinib treatment triggers programmed cell death through the downregulation of miR-30b, miR-30c, miR-221 and miR-222 and the consequent upregulation of APAF-1 and BIM in gefitinib-sensitive HCC827 and PC9 cells. We also show that gefitinib treatment does not decrease miR-30b, miR-30c, miR-221 and miR-222 expression in gefitinib-resistant Calu-1, A549 and HCC827 GR cells as a result of MET overexpression. Therefore, EGFR inhibition alone in cells overexpressing MET is not sufficient to induce the downregulation of these miRNAs and, accordingly, cell death. We show that gefitinib resistance could be overcome by MET inhibitors, which downregulate miR-30b, miR-30c, miR-221 and miR-222 and sensitize NSCLCs to gefitinib or by anti-miR-221 and anti-miR-30c, which strongly increase gefitinib sensitivity in vitro and in xenograft mouse models in vivo. Taken together, these results indicate that the modulation of specific miRNAs, such as miR-30b, miR-30c, miR-221 and miR-222, could have therapeutic applications to sensibilize lung tumors to TKI therapy. PTEN loss, by partially uncoupling mutant EGFR from downstream signaling and by activating EGFR, contributes to erlotinib resistance 28 . Previously, we found PTEN to be a miR-221 and miR-222 target 3 , making it reasonable to speculate that these two miRNAs have a role in the gefitinib resistance of NSCLC cells, not only through APAF-1 but also through PTEN regulation. Notably, overexpression of another miRNA targeting PTEN 29, 30 , miR-21, induced gefitinib resistance in HCC827 and PC9 gefitinib-sensitive cells. We also show that miR-103 and miR-203, which are upregulated after MET silencing or treatment with the MET inhibitor SU11274, induce apoptosis in gefitinib-resistant NSCLCs, reduce mesenchymal markers and increase epithelial cell junction proteins compared to wild-type Calu-1 cells by downregulating the expression of PKC-ε, SRC and Dicer.
EMT has recently been shown to have a role in acquired resistance to gefitinib in A549 cells, indicating that mesenchymal status is related to the 'inherent resistance' to gefitinib or erlotinib in NSCLCs 31 . As proposed in the model in Figure 6h , MET expression downregulates miR-103 and miR-203 and upregulates miR-221, miR-222, miR-30b and miR-30c, inducing gefitinib resistance, and epithelial-mesenchymal transition in NSCLCs. The identification of prognostic and predictive factors associated with sensitivity or resistance to anti-EGFR agents is a key area of investigation, and aberrant key signaling proteins, including RAS-MEK, AKT-mammalian target of rapamycin (mTOR) and MET kinase, have recently been recognized as key targets of investigation 8 . As activation or amplification of MET signaling contributes to TKI resistance through multiple independent mechanisms and leads to the rapid evolution of drug resistance, stratifying NSCLCs based on MET expression or MET-regulated miRNAs may allow for individualization of treatment. Such a strategy has the potential to increase treatment efficacy by eliminating unnecessary side effects of a particular therapeutic regimen in NSCLC patients who would not benefit from that specific regimen. In addition, our clinical validation studies on lung tumor specimens reveal that MET overexpression and the consequent absence of miR-103 and miR-203 can be used to identify primary lung tumors with metastatic capacity. Indeed, reduced expression of miR-103 and miR-203 could be predictive of more aggressive, early metastatic tumors. Finally, miRNAs combined with TKIs might provide a new strategy to treat NSCLCs in the future.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
Corrigendum: EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers In the version of this article initially published, the actin loading control of the western blot in Figure 1a was a rotated duplicate of the actin control in Figure 1h . The authors have not been able to provide the original control data, but they have repeated the experiment and have provided new blots (Fig. 1) that are now published as part of the correction notices linked to the HTML version and attached to the PDF version of the article. The original blots remain in both online versions of the article. In addition, Figure 6g contained a spliced gel that has now been corrected in the HTML and PDF versions of the article.
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